GTG Genetic Technologies Limited

Genetic Technologies Limited ("GTG") (NASDAQ:GENE) (ASX:GTG) announced that as reported on November 3, 2005, the United States District Court, Northern District of California had posted on its website a Stipulated Revised Case Schedule and Order (the "Order") in respect of GTG's patent dispute with Applera Corporation. The Order revealed that: -- GTG and Applera (collectively the "Parties") had reached a settlement in principle. -- A Confidential Term Sheet had been executed by the Parties and submitted to the Court. -- The Parties were working diligently to finalize a binding Settlement Agreement and associated documents by no later than Wednesday, November 9, 2005. GTG now reports that on November 11, 2005, the Court posted on its website a joint Stipulation dated the same date that had been signed and filed by the Parties, seeking additional time, until Tuesday, November 22, 2005, in order to complete and execute the settlement agreements. About Genetic Technologies Limited Genetic Technologies was the first company in the world to recognize important new applications for "non-coding" DNA (DeoxyriboNucleic Acid). The Company has since been granted patents in 24 countries around the world, securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across all genes in all multicellular species. Its three-pronged business strategy includes: 1) the global commercialization of its patents through an active licensing program; 2) the expansion of its dominant commercial genetic testing business in Australia; and, 3) the commercialization of its various research and development projects aimed at generating further intellectual property of global commercial significance. This announcement may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934 with respect to the financial condition, results and business achievements/performance of Genetic Technologies Limited and certain of the plans and objectives of its management. These statements are statements that are not historical facts. Words such as "should", "expects", "anticipates", "estimates", "believes" or similar expressions, as they relate to Genetic Technologies Limited, are intended to identify forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect Genetic Technologies' current expectations and assumptions as to future events and circumstances that may not prove accurate. There is no guarantee that the expected events, trends or results will actually occur. Any changes in such assumptions or expectations could cause actual results to differ materially from current expectations.